Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.57 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9271969 | 0.86 | L3MBTL1 (0.55) | L3MBTL1ESR1ESR2ALDH1A1MEN1 | |
| SCHEMBL9271971 | 0.86 | L3MBTL1 (0.55) | L3MBTL1ESR1ESR2ALDH1A1MEN1 | |
| SCHEMBL25285746 | 0.85 | L3MBTL1 (0.57) | L3MBTL1ESR1ESR2ALDH1A1MEN1 | |
| SCHEMBL7716645 | 0.85 | ESR1 (0.70) | L3MBTL1ESR1ESR2LMNATDP1 | |
| SCHEMBL14340687 | 0.84 | ESR1 (0.58) | L3MBTL1ESR1ESR2ALDH1A1MEN1 | |
| SCHEMBL6046251 | 0.84 | ESR1 (0.50) | L3MBTL1ESR1ESR2MEN1KMT2A | |
| SCHEMBL13687168 | 0.84 | ESR1 (0.50) | L3MBTL1ESR1ESR2ALDH1A1MEN1 | |
| SCHEMBL2295719 | 0.84 | ESR1 (0.50) | L3MBTL1ESR1ESR2ALDH1A1MEN1 | |
| SCHEMBL7629387 | 0.84 | L3MBTL1 (0.61) | L3MBTL1ESR1ESR2ALDH1A1MEN1 | |
| SCHEMBL28321416 | 0.84 | ALDH1A1 (0.46) | L3MBTL1ALDH1A1MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673818-B2 | C2-phenyl-substituted cyclic ketonols | BAYER AKTIENGESELLSCHAFT (DE) | 2014-03-18 | — | — | US | disclosed |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8334300-B2 | C2-phenyl-substituted cyclic ketonols | BAYER AKTIENGESELLSHAFT (DE) | 2012-12-18 | — | — | US | disclosed |
| US-20120238450-A1 | C2-PHENYL-SUBSTITUTED CYCLIC KETONOLS | BAYER AKTIENGESELLSCHAFT (DE) | 2012-09-20 | — | — | US | disclosed |
| US-8193120-B2 | C2-phenyl-substituted cyclic ketonols | BAYER AKTIENGESELLSCHAFT (DE) | 2012-06-05 | — | — | US | disclosed |
| US-20110183849-A1 | C2-PHENYL-SUBSTITUTED CYCLIC KETONOLS | BAYER AKTIENGESELLSCHAFT (DE) | 2011-07-28 | — | — | US | disclosed |
| US-20110143943-A1 | C2-PHENYL-SUBSTITUTED CYCLIC KETONOLS | BAYER AKTIENGESELLSCHAFT (DE) | 2011-06-16 | — | — | US | disclosed |
| US-7915282-B2 | Preparation by intramolecular cyclization | BAYER AKTIENGESELLSCHAFT (DE) | 2011-03-29 | — | — | US | disclosed |
| US-20030216260-A1 | C2-phenyl-substituted cyclic keto-enols used as pesticides and herbicides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216260-A1 | C2-phenyl-substituted cyclic keto-enols used as pesticides and herbicides | PDHX, AKR1C3, AKR1A1 | L3MBTL1 1925/4885ESR1 2576/4885ESR2 1540/4885 |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | L3MBTL1 2087/4885ESR1 1794/4885ESR2 1092/4885 |
| US-20110143943-A1 | C2-PHENYL-SUBSTITUTED CYCLIC KETONOLS | AKR1C3, PDHX, AKR1C2 | L3MBTL1 1919/4885ESR1 1594/4885ESR2 1090/4885 |
| US-20110183849-A1 | C2-PHENYL-SUBSTITUTED CYCLIC KETONOLS | AKR1C3, PDHX, AKR1C2 | L3MBTL1 1919/4885ESR1 1594/4885ESR2 1090/4885 |
| US-20120238450-A1 | C2-PHENYL-SUBSTITUTED CYCLIC KETONOLS | AKR1C3, AKR1C4, AKR1C2 | L3MBTL1 648/4885ESR1 2105/4885ESR2 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.